NCT05276063CompletedPhase 2
A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Sling Therapeutics, Inc.30 sites in 5 countries90 target enrollmentStarted: July 1, 2022Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Sling Therapeutics, Inc.
- Enrollment
- 90
- Locations
- 30
- Primary Endpoint
- Percentage of Subjects Who Are Proptosis Responders at Week 24
Study Overview
Brief Summary
The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Clinical diagnosis of Graves' Disease and/or autoimmune Hashimoto's thyroiditis associated with active moderate to severe TED with a CAS ≥ 4 (on the 7- item scale) for the most severely affected eye (primary study eye) at Screening and Baseline
- •Confirmed active TED (not sight-threatening but has an appreciable impact on daily life, with onset (as determined by patient records) within 12 months prior to the Baseline visit and usually associated with one or more of the following: lid retraction ≥ 2 mm, moderate or severe soft tissue involvement, exophthalmos ≥ 3 mm above normal for race and gender, and/or inconstant or constant diplopia.
- •Subjects must be euthyroid with the participant's baseline disease under control or have mild hypo- or hyperthyroidism (defined as free thyroxine [FT4] and free triiodothyronine levels [FT3] < 50% above or below the normal limits) at Screening.
- •Does not require immediate ophthalmic surgery, radiotherapy to orbits or other ophthalmological intervention at the time of Screening and is not planning for any such treatment during the course of the study.
Exclusion Criteria
- •Decreased best corrected visual acuity due to optic neuropathy as defined by a decrease in vision of 2 lines on the Snellen chart, new visual field defect, or color defect secondary to optic nerve involvement within the last 6 months.
- •Corneal decompensation unresponsive to medical management.
- •Previous orbital irradiation or orbital surgery.
- •Any glucocorticoid use (intravenous [IV] or oral) with a cumulative dose equivalent to >= 1g of methylprednisolone or equivalent for the treatment of TED within 3 months of Screening.
- •Prior IGF-1R inhibitor therapy for any condition.
Arms & Interventions
Placebo
Placebo Comparator
Placebo Arm
Intervention: Placebo (Drug)
Low Dose
Active Comparator
Active Arm Low Dose Linsitinib
Intervention: Linsitinib (Drug)
High Dose
Active Comparator
Active Arm High Dose Linsitinib
Intervention: Linsitinib (Drug)
Outcomes
Primary Outcomes
Percentage of Subjects Who Are Proptosis Responders at Week 24
Time Frame: 24 weeks
Proptosis response is defined as a ≥ 2 mm reduction from Baseline in the primary study eye without deterioration (≥ 2 mm increase) of proptosis in the contralateral non-study eye.
Secondary Outcomes
- Percentage of Subjects Who Are Overall Responders at Week 24(24 weeks)
- Percentage of Subjects With a CAS Value of 0 or 1 at Week 24(24 weeks)
- Change From Baseline in the Graves' Ophthalmopathy Quality of Life (GO-QoL) Questionnaire Overall Score to Week 24.(24 weeks)
Investigators
Study Sites (30)
Loading locations...
Similar Trials
Completed
Phase 2
Eurosarc Trial of Linsitinib in Advanced Ewing SarcomaRelapsed Ewing SarcomaRefractory Ewing SarcomaNCT02546544University of Oxford16
Withdrawn
Phase 2
A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative ColitisModerate to Severe Ulcerative ColitisNCT03627052Incyte Corporation
Completed
Phase 2
A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has SpreadMucosal Lentiginous MelanomaAcral Lentiginous Malignant MelanomaNCT01395121Institute of Cancer Research, United Kingdom29
Recruiting
Phase 2
Lenvatinib Plus Sintilimab in Patients with Immune Checkpoint Inhibitor Previously Treated Advanced Liver CancerIntrahepatic CholangiocarcinomaNCT05010681Fudan University25
Terminated
Phase 2
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast CancerEstrogen Receptor PositiveTriple NegativeHER2 PositiveHER2ERMBCBreast CancerMetastatic Breast CancerNCT02202746Clovis Oncology, Inc.178